H. Lundbeck A/S Class A · OMXCOP:HLUN_A

H. Lundbeck A/S Class A — Q1 2001 Earnings Presentation

10 slides from H. Lundbeck A/S Class A's earnings presentation, May 2001

  1. Slide 1: Interim Accounts First Quarter 2001

    H. Lundbeck A/S Interim Accounts First Quarter 2001 May 2001 H. Lundbeck A/S

  2. Slide 2: Agenda

    Agenda Introduction Erik Sprunk-Jansen, President & CEO Financial Results Hans Henrik Munch-Jensen, Senior Vice President & CFO Questions & Answers Erik Sprunk-Jansen, President & CEO Claus Braestrup, Executive Vice President, Research & Development Hans Henrik Munch-Jensen, Senior Vice President &

  3. Slide 3: Q1 2001 - Highlights

    Q1 2001 - Highlights n Revenue increased by 42% to DKK 1,657 million n Sales of Cipramil increased by 40% to DKK 1,093 million n Income from Celexa sales in the USA increased to DKK 257 million n Profit from operations increased by 72% to DKK 483 million n Profit before tax and after tax and minorit

  4. Slide 4: Financial results

    Financial results (DKKm) Q1 2001 Q1 2000 % change Revenue 1,163 1,657 42 Profit from operations 281 483 72 Profit before tax 358 403 12 Net profit for the period 242 253 5 H. Lundbeck A/S 4

  5. Slide 5: Revenue growth

    Revenue growth 5.6 CAGR 1996 - 2000: 25% (DKKb) 4.0 3.2 2.6 2.3 42% 1.7 1.2 1996 1997 1998 1999 2000 Q1 Q1 2000 2001 Cipramil/Celexa Other Anti-depressants Antipsychotics Other Revenue H. Lundbeck A/S 5

  6. Slide 6: Net profit ratio development

    Net profit ratio development Operating Costs Net profit ratio 5,0 4,5 4,0 30 3,5 25 3,0 DKK billion 2,5 20 2,0 15 1,5 10 1,0 5 0,5 0,0 0 19 19 19 19 20 Q1 19 19 19 19 20 Q1 Q1 96 97 98 99 00 20 97 00 96 98 99 20 20 01 01 00 COGS S,G&A R&D H. Lundbeck A/S 6

  7. Slide 7: Cash flow generation

    Cash flow generation Capex 1153 Cash Flow from Operations 1050,5 983 836 681 DKK million 461 407 276 267 216 182 34,4 -11,5 -50 1996 1997 1998 1999 2000 Q1 2000 Q1 2001 H. Lundbeck A/S 7

  8. Slide 8: In-licensed projects since June 1999

    In-licensed projects since June 1999 Compound Company Indication Gaboxadol Gaboxadol Max Max Planck Planck Institute, Institute, Munich Munich Sleep Sleep disorder disorder CEP CEP 1347 1347 Cephalon Cephalon Inc. Inc. Parkinson’s Parkinson’s disease+ disease+ Lu Lu 02-659 02-659 Neurochem Neurochem

  9. Slide 9: Lundbeck pipeline

    Lundbeck pipeline Compound Activity Indication 2001 2001 2002 2002 2003 2003 2003+ 2003+ Escitalopram Escitalopram SSRI SSRI Depression Depression Launch Memantine Memantine NMDA NMDAantagonist antagonist Alzheimer’s Alzheimer’s NDA Launch Glatiramer Glatiramer Oral OralCopaxone Copaxone acetate Mul

  10. Slide 10: H. Lundbeck A/S Q & A

    H. Lundbeck A/S Specialist in psychiatry, pioneers in neurology Q&A H. Lundbeck A/S

H. Lundbeck — Q1 2001 Earnings Presentation on 6ix